Search
Now showing items 1-3 of 3
A novle polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single dose efavirenz population pharmacokinetics in Ugandans
(Wiley-Blackwell, 2009)
AIMS Efavirenz exhibits pharmacokinetic variability causing varied clinical response. The aim was to develop an integrated population pharmacokinetic/pharmacogenetic model and investigate the impact of genetic variations, ...
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans
(Wiley-Blackwell, 2009)
AIMS
Efavirenz exhibits pharmacokinetic variability causing varied clinical response. The aim
was to develop an integrated population pharmacokinetic/pharmacogenetic model and
investigate the impact of genetic variations, ...
HIV/AIDS patients display lower relative bioavailability of Efavirenz than healthy subjects
(Adis Data Information BV., 2011)
Background: Pharmacokinetic studies of antiretroviral drugs are often conducted in adult healthy subjects, and the results are extrapolated to HIV/AIDS patients. HIV/AIDS, however, is known to cause morphological and ...